KPV

Lysine-Proline-Valine (α-MSH C-terminal Tripeptide)

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

A short tripeptide derived from alpha-MSH, studied in animal and laboratory research for anti-inflammatory mechanisms — particularly in the gut — including NF-κB pathway-related work. These preclinical findings do not establish human intestinal benefit.

Plain English

Researchers study KPV because it is a small fragment of the natural anti-inflammatory peptide alpha-MSH. In animal models and laboratory experiments, researchers have investigated whether it can influence inflammatory signaling, including NF-κB-related pathways, and intestinal-barrier processes. The current evidence set does not establish human therapeutic benefit or a generalized human safety profile.

Overview

KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). Published evidence in this record is limited to animal and in-vitro/mechanistic research, including murine inflammatory bowel disease models, human bronchial epithelial cells in vitro, and PepT1-mediated intestinal uptake studies. These sources do not establish human therapeutic efficacy, oral clinical bioavailability, or exceptional safety.

Research Summary

KPV has preclinical and mechanistic evidence in this record. Murine inflammatory bowel disease work, in-vitro bronchial epithelial research, and intestinal uptake experiments support further investigation of anti-inflammatory mechanisms, but do not establish human therapeutic efficacy, oral clinical bioavailability, or chronic safety.

Research Areas

  • Preclinical inflammatory-signaling and intestinal-uptake research

Safety & Risks

Serious Risks

  • Current evidence in this record is animal and in-vitro; human safety has not been established.
United States
Not FDA approved. The HHS interim 503A policy describes conditional enforcement discretion specifically for KPV acetate in topical and oral dosage forms, not injectable use or other forms by inference. This is not proof of safety, effectiveness or human oral bioavailability, or blanket compounding legality. The Federal Register notice describes a draft, nonbinding policy; no effective date is asserted here. Conditions include a patient-specific prescription; a State-licensed pharmacy, Federal facility or licensed physician; the exact Appendix B identity and route; FDA-registered original API manufacture compliant with CGMP, valid COAs, required quality testing and supplier validation; reporting compounded products, serious adverse events and quality issues to FDA and relevant States; patient reporting instructions and labeling 'This is a compounded drug product. Not for resale.'; a single Appendix A active ingredient; formulation-specific documentation of adequate human oral bioavailability for oral products; only a 510(k)-cleared syringe if a delivery device is co-packaged or contains the drug; and all other applicable FD&C Act requirements. This is not a 503B authorization. The interim policy lasts until a final rule addresses the substance and may be revisited for safety or quality signals.
United Kingdom
Current authorization status not established in this record
Australia
Current authorization status not established in this record
Canada
Current authorization status not established in this record

Citations & Sources